PAVM · PAVmed Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying consolidated financial statements are issued.”View the 10-Q filed May 14, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $85K | $71K | $3M | $2.5M | $377K | $500K | — | — | — | — | — | |
| $97K | $218K | $4.84M | $6.42M | $3.61M | $585K | — | — | — | — | — | |
| — | — | — | — | — | -$85K | — | — | — | — | — | |
| — | — | — | — | — | -17% | — | — | — | — | — | |
| $5.09M | $4.49M | $5.93M | $14.28M | $25.55M | $19.85M | $10.96M | $6.63M | $4.25M | $2.62M | $1.72M | |
| $886K | $917K | $11.63M | $17.58M | $19.32M | $8.9M | — | — | — | — | — | |
| $18.22M | $16.25M | $24.52M | $30.95M | $41.04M | $25.57M | $12.39M | $7.66M | $6.31M | $5.42M | $3.93M | |
| — | $0 | $559K | $2.02M | $1.78M | — | — | — | — | — | — | |
| — | $105K | $1.2M | $2.93M | $2.46M | — | — | — | — | — | — | |
| $76.02M | — | — | — | — | $54.31M | $23.35M | $14.3M | $10.56M | $8.03M | $5.65M | |
| $24.48M | $21.88M | $47.48M | $71.25M | $91.3M | — | — | — | — | — | — | |
| -$24.4M | -$21.81M | -$44.49M | -$68.8M | -$90.93M | -$54.39M | -$23.35M | -$14.3M | -$10.56M | -$8.03M | — | |
| — | -30712.68% | -1482.9% | -2751.8% | -24118.57% | -10878.6% | — | — | — | — | — | |
| — | -$21.7M | -$43.29M | -$65.86M | -$88.47M | — | — | — | — | — | — | |
| — | $21K | — | — | — | — | — | — | $2.39M | $724.68K | — | |
| — | $29K | — | — | — | — | — | — | — | — | — | |
| $2.24M | $19.34M | $72.91M | -$10.47M | -$12.31M | -$1.73M | -$12.54M | -$2.97M | -$7.61M | -$1.49M | — | |
| -$22.16M | -$2.47M | $28.43M | -$79.26M | -$103.24M | -$56.13M | -$35.89M | -$17.27M | -$18.17M | -$9.52M | — | |
| — | $0 | — | — | — | — | — | — | — | — | — | |
| -$18.63M | $401K | $39.79M | -$64.18M | -$88.98M | -$50.35M | -$34.28M | -$16.46M | -$17.97M | -$9.52M | -$5.65M | |
| — | 564.79% | 1326.37% | -2567% | -23602.92% | -10069.4% | — | — | — | — | — | |
| -$3.53M | -$2.87M | -$11.36M | -$15.09M | -$14.26M | -$5.78M | -$1.61M | -$810.89K | -$204.07K | — | — | |
| -$28.46M | -$3.77M | $31.97M | -$66.27M | -$89.26M | -$50.63M | -$34.56M | -$16.73M | -$18.75M | -$10.4M | — | |
| USD/shares | — | -$5.63 | $99.00 | -$274.80 | -$450.00 | — | — | — | — | — | — |
| USD/shares | — | -$5.63 | $15.00 | -$274.80 | — | — | — | — | — | — | — |
| shares | — | 670.47K | 322.41K | 241.05K | 197.95K | 172.26K | 105.4K | 67.11K | 49.5K | 29.99K | 28.83K |
| shares | — | 670.47K | 2.18M | 241.05K | — | 172.26K | 105.4K | 67.11K | 49.5K | 29.99K | 28.83K |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 74 similar-size Medical Devices companies (of 145 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2022 | FY2021 |
|---|---|---|
| Royalty | $100,000,000 | $100,000,000 |
| EsoGuard Test | $188,000 | — |